Details About Generic Salt ::  Aztreona

Main Medicine Class:: Antibiotic,monobactam   

(AZZ-TREE-oh-nam)
Azactam
Class: Antibiotic/monobactam

 

Drugs Class ::

 Action Inhibits bacterial cell wall synthesis.

Indications for Drugs ::

 Indications Treatment of infections of urinary tract, lower respiratory tract, skin and skin structure, intra-abdominal infections, gynecologic infections, surgical infections, and septicemia caused by susceptible microorganisms. Unlabeled use(s): Treatment of acute, uncomplicated gonorrhea in patients with penicillin-resistant gonococci.

Drug Dose ::

 Route/Dosage

Urinary Tract Infection

ADULTS: IM/IV 500 mg or 1 g q 8 to 12 hr.

Systemic Infections

ADULTS: IM/IV 1 to 2 g q 6 to 12 hr. CHILDREN: IM/IV 30 to 50 mg/kg q 4 to 8 hr.

Acute Uncomplicated Gonorrhea: IM 1 g. Max recommended dosage is 8 g/day.

Contraindication ::

 Contraindications Standard considerations.

Drug Precautions ::

 Precautions

Pregnancy: Category B. Lactation: Excreted in breast milk. Children: Safety and efficacy for use in pediatric patients < 9 months has not been established. Hypersensitivity: Reactions range from mild to life-threatening. Administer cautiously to penicillin-or cephalosporin-sensitive patients because of possible cross-reactivity. Renal impairment: Reduced dose required. Superinfection: May result in overgrowth of nonsusceptible bacterial or fungal organisms.

PATIENT CARE CONSIDERATIONS


Drug Side Effects ::

 Adverse Reactions

DERM: Rash. CNS: Seizures. GI: Diarrhea; nausea; vomiting; pseudomembranous colitis. RESP: Dyspnea. OTHER: Phlebitis/thrombophlebitis after IV administration; pain/swelling at IM injection site; fever.

Drug Mode of Action ::  

 Action Inhibits bacterial cell wall synthesis.

Drug Interactions ::

 Interactions

Beta-lactamase—inducing antibiotics (eg, cefoxitin, imipenem): May antagonize activity of aztreonam and should not be used concurrently. INCOMPATIBILITIES: Nafcillin sodium, cephradine, metronidazole: Incompatible in admixture.

Drug Assesment ::

 Assessment/Interventions

  • Obtain patient history, including drug history and any known allergies.
  • Review culture and sensitivity of organism as available.
  • Monitor patient closely for several hours after initial dose even without a history of allergy.
  • Closely monitor renal and GI function during therapy.
  • In patients with hepatic impairment, monitor for signs of hepatitis and jaundice.
  • Observe for signs of superinfection during therapy (eg, yeast infections, black hairy tongue, itching in groin area).
  • Monitor IV site continuously during administration.
  • Notify physician if signs and symptoms of hypersensitivity occur (eg, rash, shortness of breath), and stop medication.
  • Notify physician if severe GI side effects occur.
  • Call physician and stop infusion if infusion site becomes red, streaked, warm, or painful.
  • Notify physician of any signs of unusual bleeding.

Drug Storage/Management ::

 Administration/Storage

  • Follow manufacturer’s instructions for reconstitution.
  • Shake reconstituted solutions vigorously immediately after mixing. Reconstituted solutions stable at room temperature for 48 hr; stable under refrigeration for 7 days. Discard unused solutions.
  • Avoid administering concurrently with other IV medications.
  • Administer by deep IM injection in large muscle masses due to localized tissue irritation.
  • Constitute the contents of aztreonam for injection 15 or 30 ml capacity vial with ³ 3 ml of an appropriate diluent per gram of aztreonam.
  • If the contents of a 15 to 30 ml capacity vial are to be transferred to an appropriate infusion solution, each gram of aztreonam should be initially constituted with ³ 3 ml Sterile Water for Injection.

Drug Notes ::

 Patient/Family Education

  • Encourage patient to increase fluid intake to 2000 to 3000 ml per day, if allowed.
  • Inform patient to notify physician if rash or difficulty breathing is experienced.
  • If therapy is discontinued because of allergic reaction, explain significance of penicillin allergy and of potential problems with cephalosporins.
  • Caution patient against skipping doses or stopping treatment early, which could result in recurrence of symptoms and potential resistance of the organism to this product.

Disclaimer ::

The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.

We would like to keep you updated with special notifications.